Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04733274 · ClinicalTrials.gov registry record
Patient and Healthcare Professional Views on Genetic/Genomic Information and Testing
A clinical trial of Kallmann Syndrome and Hypogonadism, Hypogonadotropic, sponsored by Boston College.
- Active
- Registry status
- 227
- Enrollment target
- 2
- Study locations
NCT04733274 is a study of Kallmann Syndrome and Hypogonadism, Hypogonadotropic that is active but no longer recruiting, run by Boston College. The registered enrollment target is 227 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT04733274, a study of Kallmann Syndrome and Hypogonadism, Hypogonadotropic, is active but no longer recruiting, sponsored by Boston College.
- ACTIVE NOT RECRUITING
- Registry status
- 227 participants
- Enrollment target
- 2
- Study locations
Study Summary
Technologic advances (i.e. next generation sequencing technologies and novel bioinformatics approaches) have been drivers of scientific discovery and have deepened our understanding of the genetics and genomics of health and disease. In parallel, the falling cost of sequencing has led to screening moving from specialty clinics into the primary care setting. However, our ability to help patients and families understand these technologies and related genetic health literacy issues lag behind. These factors pose a number of questions and challenges for clinicians including: how can we best present complex genetic/genomic information to patients to ensure that patients understand the information and can make informed decisions? What are the specific information and support needs of patients and families to be able to make decisions that are in line with their values? In collaboration with investigators from the Harvard Reproductive Endocrine Sciences Center at the Massachusetts General Hospital, this project broadly aims to examine patient understanding and factors affecting decisions surrounding genetic testing. Using the paradigm of a rare genetic disorder (isolated gonadotropin releasing hormone \[GnRH\] deficiency - hypogonadotropic hypogonadism/Kallmann syndrome \[HH/KS\]) we will examine the views and perspectives of patients and healthcare professionals alike regarding genetic/genomic information and testing with the intention of identifying patient-centered responses to these unmet needs and challenges.
Conditions Studied
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
- Boston College - Chestnut Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 227 participants |
| Start Date | 2018-03-22 |
| Est. Completion | 2025-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04733274
The ClinicalTrials.gov registry entry for NCT04733274 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 227 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston College, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Kallmann Syndrome appearing as the primary indexed condition, and to 0 interventions.
NCT04733274 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04733274 about?
NCT04733274 is a clinical study titled "Patient and Healthcare Professional Views on Genetic/Genomic Information and Testing". Technologic advances (i.e. next generation sequencing technologies and novel bioinformatics approaches) have been drivers of scientific discovery and have deepened our understanding of the genetics and genomics of health and disease. In parallel, the falling cost of sequencing has led to screening m...
What is the current status of trial NCT04733274?
This trial is currently active not recruiting. The enrollment target is 227 participants. The study started on 2018-03-22. Estimated completion is 2025-12-31.
What conditions does trial NCT04733274 study?
This clinical trial studies the following conditions: Kallmann Syndrome, Hypogonadism, Hypogonadotropic.
Who is sponsoring clinical trial NCT04733274?
This trial is sponsored by Boston College, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04733274 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kallmann Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.